Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
EXEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.12 - $49.62
Previous CloseN/A
Volume463.09K
Average Volume (3M)3.44M
Market Cap
$10.01B
Enterprise Value$11.92B
Total Cash (Recent Filing)$791.10M
Total Debt (Recent Filing)$179.84M
Price to Earnings (P/E)17.7
Beta0.89
Next Earnings
Nov 04, 2025EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.75
Shares Outstanding269,202,500
10 Day Avg. Volume2,385,399
30 Day Avg. Volume3,441,911
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue5.35
Enterprise Value/Gross Profit5.54
Enterprise Value/Ebitda14.93
Forecast
1Y Price Target
$45.00Price Target Upside20.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Drug ApprovalThe probability of approval for the combination of zanzalintinib and Tecentriq has been increased to 80% from a prior estimate of 40%.
Financial PerformanceExelixis recorded a higher diluted net income per share than previously forecasted, indicating better-than-expected profitability.
Bears Say
Clinical TrialsThe company announced that zanza did not meet the threshold for advancement into Ph3 portion of the STELLAR-305 trial in 1L head-and-neck squamous cell carcinoma (HNSCC).
Revenue MissQ2 revenues of $568M missed the consensus estimate of $578M.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $25.12 and its highest was $49.62 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $10.01B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Nov 04, 2025 which is in 60 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Jul 28, 2025. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.668 by $0.082.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.68.
How many shares outstanding does Exelixis have?
Exelixis has 269,202,500 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.75 in its last earnings report, beating expectations of $0.668. Following the earnings report the stock price went down -16.783%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
Exelixis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.00 (20.39% Upside)
$45.00 (20.39% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 6.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.95%
12-Months-Change
Fundamentals
Return on Equity
29.00%
Trailing 12-Months
Asset Growth
-3.43%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for cancer treatment. Headquartered in Alameda, California, Exelixis is primarily involved in the oncology sector, offering a range of products designed to improve the lives of patients with various types of cancer. The company’s core product is cabozantinib, marketed under the brand names Cometriq and Cabometyx, which is used for the treatment of multiple cancer indications, including renal cell carcinoma and hepatocellular carcinoma.
EXEL Company Deck
EXEL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Exelixis with strong revenue growth, new approvals, and positive clinical trial results. However, there were some challenges including the discontinuation of a head and neck cancer trial and higher gross to net deductions. Overall, strong financial performance and strategic advancements in oncology support a positive sentiment.View all EXEL earnings summariesEXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$45.00
▲(20.39% Upside)
Technical Analysis
Ownership Overview
3.82% Insiders
25.42% Mutual Funds
24.24% Other Institutional Investors
17.65% Public Companies and Individual Investors